摘要
乳中特定的活性肽可以有效地抑制血管紧张素转化酶(ACE)的活性,起到抗高血压的作用。但是乳源ACE抑制肽由于结构不同,经口服后并不都能通过小肠黏膜进入血液循环,因此并不都具有降血压的功效,口服生物利用度也较低。本文介绍乳源ACE抑制肽的研究现状和活性评价方法,概述利用Caco-2细胞模型研究乳源ACE抑制肽在小肠中的摄入、小肠细胞中滞留代谢及小肠外排机制的研究进展,并对如何提高乳源ACE抑制肽的口服生物利用度提出展望。
The specific active peptides in milk can inhibit the activity of angiotensinⅠ-converting enzyme effectively to execute antihypertensive effect.Due to different structures of milk-derived ACE inhibitory peptides,the peptides are not able to pass through the intestinal mucosa into blood circulation when administered orally.Therefore,not all ACE inhibitory peptides have the function of lowering blood pressure and a low oral bioavailability.This article has introduced current research status and activity evaluation as well as the intestinal absorption mechanism of milkderived ACE inhibitory peptides,which includes intestinal ingestion,metabolic activity and intestinal excretion using Caco-2 cell model.In addition,a prospect of improving oral bioavailability of milk-derived ACE inhibitory peptides has also been proposed.
出处
《食品科学》
EI
CAS
CSCD
北大核心
2013年第9期330-335,共6页
Food Science
基金
国家自然科学基金青年科学基金项目(31101314)
江苏省自然科学基金项目(BK2011787)
江苏省教育厅高校自然科学基金项目(10KJB550003)
南京师范大学特聘教授
高层次人才科研启动基金项目(184070H2B08)